Innate Pharma co-organise un symposium scientifique en prsence dexperts de lImmunotherapie New York le 3 octobre 2024

IPHA Stock  USD 1.69  0.11  6.11%   
About 62% of Innate Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Innate Pharma suggests that many traders are alarmed. The current market sentiment, together with Innate Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Innate Pharma stock news signals to limit their universe of possible portfolio assets.
  
Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024

Read at businesswire.com
businesswire News
  

Innate Pharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Innate Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Innate Pharma Fundamental Analysis

We analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Innate Pharma is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Innate Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Innate Pharma stock to make a market-neutral strategy. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics with similar companies.

Peers

Innate Pharma Related Equities

CSBRChampions Oncology   12.09   
0%
100.0%
APMAptorum Group   5.33   
0%
44.0%
DYAIDyadic International   3.77   
0%
31.0%
STTKShattuck Labs   2.31   
0%
19.0%
INBXInhibrx   1.00   
0%
8.0%
ANEBAnebulo Pharmaceuticals   0.64   
0%
5.0%
MOLNMolecular Partners   0.36   
0%
2.0%
ADXNAddex Therapeutics   1.38   
11.0%
0%
MNOVMediciNova   1.74   
14.0%
0%
ELYMEliem Therapeutics   1.90   
15.0%
0%
IPSCCentury Therapeutics   4.08   
33.0%
0%
HCWBHCW Biologics   4.76   
39.0%
0%

Complementary Tools for Innate Stock analysis

When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format